NCT06325683 2026-04-21
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Suspended
Clinical Trials
8 trialsNCT03575611 2026-04-15
Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Suspended
NCT03375307 2026-04-13
Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes
National Cancer Institute (NCI)
Phase 2 Suspended
NCT05554380 2026-04-13
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Suspended
NCT06254911 2026-01-27
Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma
Emory University
Phase 2 Suspended
NCT06575686 2026-01-21
Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
City of Hope Medical Center
Phase 2 Suspended
NCT06112847 2025-12-10
Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma
City of Hope Medical Center
Phase 2 Suspended
NCT05764395 2024-10-10
Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors
Vanderbilt-Ingram Cancer Center
Phase 2 Suspended